

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Hopper
Date of last notice	30 January 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Deborah Anne Coleman (a related party of Mr Hopper) Moreglade Pty Ltd (a controlled entity of Mr Hopper) Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper) Alexandra Jane Hopper (a related party of Mr Hopper) Horatia Isabelle Hopper (a related party of Mr Hopper) India Lucy Hopper (a related party of Mr Hopper) Scarlett Augusta Wiseman Hopper (a related party of Mr Hopper)
Date of change	22 June 2015

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p> <p>Paul Edward Alexander Hopper</p> <p>Deborah Anne Coleman (a related party of Mr Hopper)</p> <p>Moreglade Pty Ltd (a controlled entity of Mr Hopper)</p> <p>Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper)</p> <p>Alexandra Jane Hopper (a related party of Mr Hopper)</p> <p>Horatia Isabelle Hopper (a related party of Mr Hopper)</p> <p>India Lucy Hopper (a related party of Mr Hopper)</p> <p>Scarlett Augusta Wiseman Hopper (a related party of Mr Hopper)</p>	<p>516,667 Fully paid ordinary shares</p> <p>1,676,667 Fully paid ordinary shares</p> <p>1,433,334 Fully paid ordinary shares</p> <p>2,605,334 Fully paid ordinary shares</p> <p>33,334 Fully paid ordinary shares</p> <p>33,334 Fully paid ordinary shares</p> <p>33,334 Fully paid ordinary shares</p> <p>33,334 Fully paid ordinary shares</p>
<p>Class</p>	<p>Fully paid ordinary shares</p>
<p>Number acquired</p> <p>Paul Edward Alexander Hopper</p> <p>Deborah Anne Coleman (a related party of Mr Hopper)</p> <p>Moreglade Pty Ltd (a controlled entity of Mr Hopper)</p> <p>Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper)</p>	<p>450,000 Fully paid ordinary shares</p> <p>540,000 Fully paid ordinary shares</p> <p>900,000 Fully paid ordinary shares</p> <p>783,000 Fully paid ordinary shares</p>
<p>Number disposed</p>	<p>Nil</p>
<p>Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small></p>	<p>In consideration for the acquisition of Pathway Oncology Pty Ltd Milestone 1 satisfaction.</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held after change</p> <p>Paul Edward Alexander Hopper</p> <p>Deborah Anne Coleman (a related party of Mr Hopper)</p> <p>Moreglade Pty Ltd (a controlled entity of Mr Hopper)</p> <p>Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper)</p> <p>Alexandra Jane Hopper (a related party of Mr Hopper)</p> <p>Horatia Isabelle Hopper (a related party of Mr Hopper)</p> <p>India Lucy Hopper (a related party of Mr Hopper)</p> <p>Scarlett Augusta Wiseman Hopper (a related party of Mr Hopper)</p>	<p>966,667 Fully paid ordinary shares</p> <p>2,216,667 Fully paid ordinary shares</p> <p>2,333,334 Fully paid ordinary shares</p> <p>3,388,334 Fully paid ordinary shares</p> <p>33,334 Fully paid ordinary shares</p> <p>33,334 Fully paid ordinary shares</p> <p>33,334 Fully paid ordinary shares</p> <p>33,334 Fully paid ordinary shares</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Allotment of shares in consideration for acquisition of Pathway Oncology Pty Ltd Milestone 1 satisfaction and as approved by shareholders at the Company's General Meeting of shareholders held on 9 May 2014.</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
<p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p>	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Steven Lee Yatomi-Clarke
Date of last notice	3 December 2014

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Arrow Health Ltd <Berbay Family A/C> (a controlled entity of Mr Yatomi-Clarke) Novetera Pty Ltd <SAYC Super Fund A/C> (a controlled entity of Mr Yatomi-Clarke) Alexandra Elizabeth Yatomi-Clarke
Date of change	22 June 2015
No. of securities held prior to change	816,000 Fully paid ordinary shares (16,320,000 pre-consolidation)
Class	Fully paid ordinary shares
Number acquired	1,224,000 Fully paid ordinary shares
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	In consideration for the acquisition of Pathway Oncology Pty Ltd Milestone 1 satisfaction.

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	2,040,000 Fully paid ordinary shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Allotment of shares in consideration for acquisition of Pathway Oncology Pty Ltd Milestone 1 satisfaction and as approved by shareholders at the Company's General Meeting of shareholders held on 9 May 2014.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.